Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a...
November 06, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 27, 2018 16:01 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Commencement of Public Offering of Common Stock

SAN DIEGO, June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
June 20, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial

– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
April 07, 2017 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947

LA JOLLA, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
March 06, 2017 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib

LA JOLLA, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
October 14, 2015 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Appoints Thomas Malley to Board of Directors

LA JOLLA, Calif., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company, today announced the appointment of Thomas Malley to its board of...